Quick Takeaways
- This page summarizes Cameron Turtle's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
- 3 reported transactions and 0 derivative rows are listed below.
- Filing timestamp: 06 Jan 2026, 21:36.
Cameron Turtle - 02 Jan 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)
- Signature
- /s/ Heidy King-Jones, as Attorney-in-Fact
- Issuer symbol
- SYRE
- Transactions as of
- 02 Jan 2026
- Net transactions value
- -$460,134
- Form type
- 4
- Filing time
- 06 Jan 2026, 21:36:32 UTC
- Previous filing
- 03 Dec 2025
- Next filing
- 13 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Cameron Turtle filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 06 Jan 2026."
What Changed
- Previous filing in this sequence was filed on 03 Dec 2025.
- Current net transaction value: -$460,134.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Turtle Cameron | Chief Executive Officer, Director | 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM | /s/ Heidy King-Jones, as Attorney-in-Fact | 06 Jan 2026 | 0001758363 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SYRE | Common Stock | Sale | $387,243 | -12,709 | -1.9% | $30.47 | 674,198 | 02 Jan 2026 | Direct | F1, F2, F3 |
| transaction | SYRE | Common Stock | Sale | $69,652 | -2,191 | -0.32% | $31.79 | 672,007 | 02 Jan 2026 | Direct | F1, F3, F4 |
| transaction | SYRE | Common Stock | Sale | $3,239 | -100 | -0.01% | $32.39 | 671,907 | 02 Jan 2026 | Direct | F1, F3, F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. |
| F2 | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $31.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. |
| F3 | Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. |
| F4 | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.29 to $32.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F5 | The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $32.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |